This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frappaz, D. Articles by Zucker, J. M. Search for Related Content PubMed PubMed Citation Articles by Frappaz, D. Articles by Zucker, J. M.

LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis

From the Centre L. Bérard, Lyon; Institut Curie, Paris; Hôpital de la Timone, Marseille; Hôpital Nord, Saint Etienne; and Centre Hospitalo-Universitaire, Besançon, France.

Address reprint requests to D. Frappaz, MD, Centre Léon Bérard, 28 rue Laënnec 69373, Lyon Cédex 08, France; email frappaz{at}lyon fnclcc.fr.

PURPOSE: To tailor postinduction therapy for stage 4 neuroblastoma in children who are older than 1 year at diagnosis according to status after induction.

PATIENTS AND METHODS: From March 1987 to December 1992, 99 patients who were consecutively admitted were included in the Lyon-Marseille-Curie East of France (LMCE)3 strategy. After induction with the French Society of Pediatric Oncology NB87 regimen and surgery, patients who were in complete remission immediately proceeded to consolidation therapy with vincristine, melphalan, and fractionated total-body irradiation (VMT). All other patients underwent a postinduction strategy before VMT, either an additional megatherapy regimen or further chemotherapy with etoposide/carboplatin.

RESULTS: The progression-free survival (PFS) is 29% at 7 years from diagnosis, which compares favorably with that of a similar cohort of 72 patients previously reported by our group (LMCE1; PFS of 20% at 5 years and 8% at 14 years, P = .004). In the multivariate analysis, only age younger than 3 years at diagnosis (P = .0085) and achievement of complete or very good partial remission after NB87 and surgery (P = .00024) remained significant. The PFS of the 87 patients who were included in the postinduction strategy was significantly better than that of the comparable 62 patients on the LMCE1 study (32% v 11% at 7 years; P = .005).

CONCLUSION: The progressive improvements in the LMCE results over the last 10 years suggest that improvements in supportive care measures and increases in each component of this strategy (induction, postinduction, consolidation) may all contribute to increased survival rates.

This article has been cited by other articles:

				R. E. George, S. Li, C. Medeiros-Nancarrow, D. Neuberg, K. Marcus, R. C. Shamberger, M. Pulsipher, S. A. Grupp, and L. Diller High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell-Supported Transplantation: Long-Term Survival Update J. Clin. Oncol., June 20, 2006; 24(18): 2891 - 2896. [Abstract] [Full Text] [PDF]

				R. E. George, W. B. London, S. L. Cohn, J. M. Maris, C. Kretschmar, L. Diller, G. M. Brodeur, R. P. Castleberry, and A. T. Look Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study J. Clin. Oncol., September 20, 2005; 23(27): 6466 - 6473. [Abstract] [Full Text] [PDF]

				C. Subramanian, A. W. Opipari Jr., X. Bian, V. P. Castle, and R. P. S. Kwok Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors PNAS, March 29, 2005; 102(13): 4842 - 4847. [Abstract] [Full Text] [PDF]

				D. Valteau-Couanet, J. Michon, A. Boneu, C. Rodary, Y. Perel, C. Bergeron, H. Rubie, C. Coze, D. Plantaz, F. Bernard, et al. Results of Induction Chemotherapy in Children Older Than 1 Year With a Stage 4 Neuroblastoma Treated With the NB 97 French Society of Pediatric Oncology (SFOP) Protocol J. Clin. Oncol., January 20, 2005; 23(3): 532 - 540. [Abstract] [Full Text] [PDF]

				C. S. Kretschmar, M. Kletzel, K. Murray, P. Thorner, V. Joshi, R. Marcus, E. I. Smith, W. B. London, and R. Castleberry Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study J. Clin. Oncol., October 15, 2004; 22(20): 4119 - 4126. [Abstract] [Full Text] [PDF]

				H. M. Katzenstein, S. L. Cohn, R. M. Shore, D. M.E. Bardo, P. R. Haut, M. Olszewski, J. Schmoldt, D. Liu, A. W. Rademaker, and M. Kletzel Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma J. Clin. Oncol., October 1, 2004; 22(19): 3909 - 3915. [Abstract] [Full Text] [PDF]

				P. P. McKenzie, M. K. Danks, R. W. Kriwacki, and L. C. Harris p21Waf1/Cip1 Dysfunction in Neuroblastoma: A Novel Mechanism of Attenuating G0-G1 Cell Cycle Arrest Cancer Res., July 1, 2003; 63(13): 3840 - 3844. [Abstract] [Full Text] [PDF]

				K. K. Matthay, V. Edeline, J. Lumbroso, M. L. Tanguy, B. Asselain, J. M. Zucker, D. Valteau-Couanet, O. Hartmann, and J. Michon Correlation of Early Metastatic Response by123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma J. Clin. Oncol., July 1, 2003; 21(13): 2486 - 2491. [Abstract] [Full Text] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, M. S. Lo Piccolo, B. H. Kushner, K. Kramer, and N.-K. V. Cheung Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma J. Clin. Oncol., March 15, 2003; 21(6): 1087 - 1093. [Abstract] [Full Text] [PDF]

				X. Bian, A. W. Opipari Jr., A. B. Ratanaproeksa, A. E. Boitano, P. C. Lucas, and V. P. Castle Constitutively Active NFkappa B Is Required for the Survival of S-type Neuroblastoma J. Biol. Chem., October 25, 2002; 277(44): 42144 - 42150. [Abstract] [Full Text] [PDF]

				M. Kletzel, H. M. Katzenstein, P. R. Haut, A. L. Yu, E. Morgan, M. Reynolds, G. Geissler, M. H. Marymount, D. Liu, J. A. Kalapurakal, et al. Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study J. Clin. Oncol., May 1, 2002; 20(9): 2284 - 2292. [Abstract] [Full Text] [PDF]

				J. Mora, W. L. Gerald, J. Qin, and N.-K. V. Cheung Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience Oncologist, June 1, 2001; 6(3): 263 - 268. [Abstract] [Full Text] [PDF]

				D. A. Tweddle, A. J. Malcolm, N. Bown, A. D. J. Pearson, and J. Lunec Evidence for the Development of p53 Mutations after Cytotoxic Therapy in a Neuroblastoma Cell Line Cancer Res., January 1, 2001; 61(1): 8 - 13. [Abstract] [Full Text]

				D. Huang, J. L. Rutkowski, G. M. Brodeur, P. M. Chou, J. L. Kwiatkowski, A. Babbo, and S. L. Cohn Schwann Cell-conditioned Medium Inhibits Angiogenesis Cancer Res., November 1, 2000; 60(21): 5966 - 5971. [Abstract] [Full Text]

				X. Bian, L. M. McAllister-Lucas, F. Shao, K. R. Schumacher, Z. Feng, A. G. Porter, V. P. Castle, and A. W. Opipari Jr. NF-kappa B Activation Mediates Doxorubicin-induced Cell Death in N-type Neuroblastoma Cells J. Biol. Chem., December 21, 2001; 276(52): 48921 - 48929. [Abstract] [Full Text] [PDF]